BRCA1 and medullary thyroid gland carcinoma: Although this increase is not statistically significant (data not shown), it is in agreement with previous analyses that describe genomic gains/amplifications at 13q34 in ER-negative tumors, basal-like tumors, BRCA1-associated breast cancers, and medullary carcinomas [10,16,38,39].